Immunofoco

Immunofoco is an innovative enterprise that utilizes immune cell therapy technology platforms and combines clinical innovation methods to develop novel solid tumor treatment drugs. It commenced operations in September 2020 in Zhangjiang, Shanghai. The company was co-founded by a team of scientists and industry elites, with the founding team covering all aspects of industry-academia-research-clinical collaboration. Core members have successfully driven the marketing application of China's first CAR-T drug, possessing extensive experience in cell drug development and industrialization. The company has established the "Pericruiser®" technology platform, addressing two major industry pain points—solid tumors and universal cell therapies—with a primary focus on gastrointestinal cancer indications. In terms of progress, Immunofoco advanced its first project into the IIT clinical trial stage in less than a year, with plans to file an IND product in 2022.